Abstracts Archive - Page 561 of 2425 - ACR Meeting Abstracts

Abstract Number: 0131 • ACR Convergence 2021
Association of Numeracy with Medication Non-Adherence in Systemic Lupus Erythematosus
Mithu Maheswaranathan¹, Amanda Eudy², Ann Barr², Catherine Howe³, Stacy Bailey⁴, Susan Hastings¹, Jennifer Rogers², Jayanth Doss², Lisa Criscione-Schreiber¹, Rebecca Sadun², Megan Clowse⁵ and Kai Sun¹, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Northwestern University, Evanston, IL, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Over 33% of U.S. adults have limited health literacy or numeracy. Limited health literacy and numeracy have been associated with higher disease activity and…
Abstract Number: 0134 • ACR Convergence 2021
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Sebastian Bruera¹, Xiudong Lei², Xerxes Pundole², Hui Zhao², Sharon Giordano², Surabhi Vinod¹ and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus (SLE) who develop breast cancer (BC), may receive different therapies (e.g. radiation) than women with BC who do not…
Abstract Number: 0133 • ACR Convergence 2021
Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus
Erica Rosen¹ and Megan Krause², ¹University of Kansas, Kansas City, MO, ²University of Kansas, Kansas City, KS
Background/Purpose: Females with systemic lupus erythematosus have increased rates of cervical cancer especially if on immunosuppressive therapy. The American Cancer Society reports the incidence of…
Abstract Number: 0132 • ACR Convergence 2021
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Jesse Dabit¹, Mehmet Hocaoglu², Maria Valenzuela-Almada³, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Rachel Giblon¹, Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disease associated with significant morbidity and mortality. Although the survival rate for SLE patients has…
Abstract Number: 0127 • ACR Convergence 2021
Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India
Arun Tiwari¹, Mithun CB², Lalitha Biswas³, Sandeep Surendran³, Vishal Marwaha³, Pranav Chickermane³ and Amisha Shahul³, ¹Amrita Institute of Medical Sciences, Ernakulam, India, ²Amrita Institute of Medical Sciences, Muvattupuzha, India, ³Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Interleukin-1 receptor antagonist (IL-1Ra) variable number of tandem repeats (VNTR) polymorphism is a known to influence the production of IL-1Ra and has been considered…
Abstract Number: 0138 • ACR Convergence 2021
Treatment with Adalimumab in Patients with Chronic Inflammatory Rheumatic Diseases: A Study of Treatment Trajectories on a Patient Level in Clinical Practice
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Adalimumab (ADA) retention rates are impaired in patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) due to loss of efficacy and adverse events, causing…
Abstract Number: 0137 • ACR Convergence 2021
Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019
Edward Neuberger¹, Tu My To¹, Arpamas Seetasith¹, Stella Arndorfer² and Christopher Wallick¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, South San Francisco, CA
Background/Purpose: Seasonal influenza poses a large burden on the healthcare system. Patients with certain chronic diseases, such as rheumatoid arthritis (RA), are especially vulnerable to…
Abstract Number: 0135 • ACR Convergence 2021
Comparing Rheumatoid Arthritis (RA), Psoriatic Arthritis (PA) and Systemic Lupus Erythematosus (SLE) Total Cost of Care (TCC) in Those with Optimally Managed Depression to Those with Sub-optimally Managed Depression
Joseph Couto¹, Elisea Avalos-Reyes², Amanda McCarthy³, Olga Matlin⁴, Michele Hamburger⁵, Gerard Maher⁶ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Irving, TX, ³CVS Health, Greensboro, GA, ⁴CVS Health, Northbrook, IL, ⁵Frances Hamburger Institute, Hauppauge, NY, ⁶Frances Hamburger Institute, Hauppaugue, NY
Background/Purpose: Rheumatic diseases (RD) are characterized by systemic signs and symptoms, including articular and extra-articular manifestations. Three common forms of RDs are RA, PsA and…
Abstract Number: 0139 • ACR Convergence 2021
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
Alexis Ogdie-Beatty¹, Marina Magrey², Robert Fitzsimmons¹, Shahrzad Abdollahi¹, Ana Biljan³, Christopher Saffore⁴ and Jessica Walsh⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ³Abbvie Inc., Chicago, IL, ⁴AbbVie, North Chicago, IL, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: While recommendations for the treatment of ankylosing spondylitis (AS) are largely aligned across various guidelines,1,2 there remains variability in the treatment. Patients with inflammatory…
Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois¹, Ines Colmegna³, Carol Hitchon⁴, Louis Bessette⁵, Glen Hazlewood⁶, Carter Thorne⁷, Janet Pope⁸, Gilles Boire⁹, Diane Tin¹⁰, Edward Keystone¹¹, Vivian Bykerk¹², Susan Bartlett¹ and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
Abstract Number: 0140 • ACR Convergence 2021
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
Jana Ziob¹, Charlotte Behning¹, Peter Brossart², Thomas Bieber¹, Dagmar Wilsmann-Theis³ and Valentin Schäfer⁴, ¹University Hospital Bonn, Bonn, Germany, ²Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany
Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was…
Abstract Number: 0136 • ACR Convergence 2021
Underutilization of Mental Health Services in a Busy Tertiary Care Rheumatology Facility
David Lim¹, Manushi Aggarwal¹ and Vaneet Sandhu², ¹Loma Linda University Health, Redlands, CA, ²Loma Linda University Health, Loma Linda, CA
Background/Purpose: Mental health disorders are prevalent in patients with rheumatic diseases, particularly since many of these diseases present early, have a chronic course, and significantly…
Abstract Number: 0130 • ACR Convergence 2021
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
Joseph Tkacz¹, Allison Perry¹, Helen Varker¹, Richard Bizier¹, Robert Ortmann² and Sandra Sze-jung Wu³, ¹IBM Watson Health, Bethesda, MD, ²AstraZeneca, Greenwood, IN, ³AstraZeneca, Wilmington, DE
Background/Purpose: Current literature characterizing the economic and clinical burden of systemic lupus erythematosus (SLE) is outdated and often does not consider SLE disease severity, which…
Abstract Number: 0111 • ACR Convergence 2021
Risk of Hospitalization, Admission to Intensive Care and Mortality Due to COVID-19 in Patients with Rheumatic Diseases: A Population-based Matched Cohort Study
Ana Michelle Avina-Galindo¹, Shelby Marozoff¹, Zahra Fazal¹, Jessie Kwan¹, Na Lu¹, Alison Hoens², Diane Lacaille³, Jacek Kopec⁴, Hui Xie⁵ and J. Antonio Avina-Zubieta³, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada Arthritis Patient Advisory Board, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: New cases of the novel coronavirus disease (COVID-19) continue to occur even one year since the declaration of a global pandemic. Although most people…
Abstract Number: 0082 • ACR Convergence 2021
Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Doruk Erkan¹, Karen Costenbader² and On Behalf of New APS Classification Criteria Development Case Collectors¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Few studies have evaluated the role of environmental factors in APS. While antiphospholipid antibodies (aPL) may be induced by environmental stiumuli, e.g., viruses, cardiovascular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].